Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Frequently asked questions
What sector does Ardelyx, Inc (ARDX) operate in?
Ardelyx, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Ardelyx, Inc (ARDX) current stock price?
As of the latest data, Ardelyx, Inc stock price is $3.91, with a previous close of $4.06. Ardelyx, Inc lost -$0.16 in the last trading session, representing a -3.82% loss.
What is Ardelyx, Inc (ARDX) current market capitalization?
Ardelyx, Inc market cap is approximately 973.08 million.
What is Ardelyx, Inc (ARDX) Earnings Per Share (EPS)?
The trailing EPS is -$0.23, and the forward EPS is $0.52.
What is Ardelyx, Inc (ARDX) EBITDA?
Ardelyx, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.13 million.
Does Ardelyx, Inc (ARDX) pay dividends?
No. Ardelyx, Inc does not pay a dividend.
How did Ardelyx, Inc (ARDX) perform in its most recent earnings report?
In the last report (June 30, 2026), Ardelyx, Inc posted an EPS surprise of -40% and a revenue surprise of -0.63%.
What is Ardelyx, Inc (ARDX) beta (volatility) score?
Ardelyx, Inc has a beta of 0.731, indicating lower volatility than the overall market.
